Coherus supplements proxy for UDENYCA sale; discloses JPMorgan valuation & cash flow projections

Coherus Oncology, Inc.

Four shareholder complaints filed in NYC Supreme Court alleging proxy deficiencies; company denies merit.
Voluntarily adds JPMorgan's selected transaction analysis: implied consideration ~$530M (base plus risk-adjusted earnout).
Discloses UDENYCA unlevered free cash flow: $51M in 2025E, rising to $105M by 2029E, with revenue $186M in 2025E.
Special meeting to approve sale to Intas Pharmaceuticals remains scheduled for March 11, 2025.
Company believes no supplemental disclosures are legally required but provides them to avoid litigation delay.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.